Lawmakers Keep Merck, Schering-Plough In Hot Seat

Law360, New York (February 12, 2008, 12:00 AM EST) -- Messages posted on a Web site frequented by pharmaceutical sales representatives have led two congressmen to further question the handling of a study by Merck & Co. Inc. and Schering-Plough Corp. for their cholesterol drug Vytorin.

In a letter Monday, Reps. John Dingell (D-Mich.) and Bart Stupak (D-Mich.) questioned why anonymous posters on cafepharma.com were talking about the controversial Enhance trial for Vytorin nine months before the companies had released data about the study.

“These Web site entries are obviously troubling and raise again the question...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.